These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12215010)

  • 1. Cancer immunotherapy targeting WT1 protein.
    Sugiyama H
    Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
    Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer antigen WT1-targeting treatment for the malignancies].
    Oka Y; Kawase I
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
    Elisseeva OA; Oka Y; Tsuboi A; Ogata K; Wu F; Kim EH; Soma T; Tamaki H; Kawakami M; Oji Y; Hosen N; Kubota T; Nakagawa M; Yamagami T; Hiraoka A; Tsukaguchi M; Udaka K; Ogawa H; Kishimoto T; Nomura T; Sugiyama H
    Blood; 2002 May; 99(9):3272-9. PubMed ID: 11964293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
    Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
    Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 as a novel target antigen for cancer immunotherapy.
    Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
    Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Sugiyama H
    Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.